John Barrett
The recognition of the curative potential of the graft-versus-leukemia effect for patients with Acute Myeloid Leukemia (AML) undergoing stem cell
transplantation, and the emergence of immunotherapy as a powerful weapon to treat cancer, has spurred the exploration of the immune landscape
of AML to apply immunotherapeutic approaches to curing the disease. While current concepts of cancer immunology and immunotherapy
have relevance, there are also unique aspects of immune dysregulation in AML to be considered when designing rational immunotherapy for
this leukemia. This is timely because rapid advances in cancer immune-biology, together with technological developments have opened up the
field of immunotherapy for malignant disease. This talk summarizes current knowledge of AML immune-biology together with a description of
new immunotherapies to counter immunosuppression and immune evasion by AML. Recent advances in treatment with recombinant antibodies,
adoptive cell therapy and vaccines and their future promise in AML treatment are discussed.
